Radium-223 dichloride (radium-223) is an α-emitting radionuclide approved for treating metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastases and no visceral disease. Although efficacy and safety were established in pivotal trials, real-world evidence in Asian populations, particularly Taiwan, remains limited. Here we report the final analysis of the observational RAdium-223 dichloride in routine clinical Practice settings In Taiwan (RAPIT) study. This prospective, multicenter, single-arm, noninterventional study included patients with mCRPC with symptomatic bone metastases receiving radium-223 in clinical practice in Taiwan. The primary objective was to evaluate safety, including treatment-emergent and drug-related adverse events and long-term safety. Effectiveness outcomes were secondary endpoints. A total of 224 patients were enrolled; most had ≤ 20 bone metastases (69.2
Randomized trials have established the efficacy of adjuvant and neoadjuvant immunotherapy in resectable stage III melanoma, yet how these findings translate into real-world practice remains unclear. Using the National Cancer Database (NCDB), we evaluated treatment patterns and survival outcomes among 14,164 patients with clinical stage III melanoma treated with surgery alone, adjuvant immune checkpoint inhibitors (ICI), adjuvant targeted therapy, neoadjuvant immunotherapy, or neoadjuvant targeted therapy. Of the 14,164 patients, 6889 (48.6
Poly(ADP-ribose) polymerase (PARP) inhibitors are established treatment options for patients with germline BRCA1/2-mutated hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer. However, evidence regarding their optimal sequencing after cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor-based therapy remains limited. To evaluate the real-world efficacy and safety of olaparib after prior CDK4/6 inhibitor plus endocrine therapy, with particular emphasis on treatment sequence and line of olaparib use. This multicenter real-world retrospective study included patients with HR+/HER2− metastatic breast cancer harboring germline BRCA1/2 pathogenic variants who received olaparib after prior CDK4/6 inhibitor plus endocrine therapy. We retrospectively collected clinical characteristics, treatment sequence, response, survival outcomes, and olaparib-related adverse events. We evaluated progression-free survival (PFS), objective response rate (ORR), and treatment-related adverse events. We included 52 patients from 28 institutions. Median age at olaparib initiation was 49.9 years [interquartile range (IQR), 40.2–59.0 years], and median follow-up was 12.84 months (95
Immune-related adverse events (irAEs) are common complications of immune checkpoint inhibitor (ICI) therapy and frequently require immunosuppressive treatment. Infliximab is commonly used for steroid-refractory irAEs; however, the optimal dosing strategy remains unclear. The study objective is to evaluate the efficacy and safety of infliximab and assess the impact of dosing strategies across diverse irAEs. We retrospectively analyzed patients treated at our institution who developed irAEs requiring infliximab. Patients were grouped according to infliximab starting dose and total number of doses received. Treatment outcomes and infliximab-related adverse events were assessed. The study included 457 patients with irAEs treated with infliximab. Among 443 patients receiving 5 mg/kg infliximab, 342 received 1–2 doses and 101 received ≥ 3 doses. Patients receiving ≥ 3 doses had higher 8-week remission rates than those receiving 1–2 doses (75 versus 49
Vibostolimab, an anti–T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) antibody, showed antitumor activity with pembrolizumab in non–small-cell lung cancer. The KEYVIBE-008 study evaluated vibostolimab coformulated with pembrolizumab (vibostolimab/pembrolizumab) plus etoposide and platinum-based chemotherapy (EP) versus atezolizumab plus EP as first-line therapy for extensive-stage small-cell lung cancer. Participants aged ≥18 years with untreated extensive-stage small-cell lung cancer were randomized 1:1 to vibostolimab/pembrolizumab (200 mg each) or atezolizumab (1200 mg) every 3 weeks, with EP and cisplatin/carboplatin for the first four cycles. The primary endpoint was overall survival. The prespecified interim analysis included a non-binding futility analysis of overall survival (futility threshold for actual number of events, P = 0.4816). Four hundred and sixty participants were randomized (both arms, n = 230). Median time from randomization to data cutoff (4 June, 2024) was 16.6 (range 11.3‒26.1) months. The prespecified futility criterion for overall survival was met (hazard ratio 1.26; 95
